Company / R&D Expense
Oruka Therapeutics, Inc. R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$75.1M
FY2024
5-year range
$1.0M / $75.1M
FY2020-FY2024
Trend
+7309.7%
vs FY2023
Sector context
#162 of 210
Health Care
What the data says
R&D Expense changed +7310% YoY in FY2024, a notable deviation from the 9-year average annual change of +839%.
Based on SEC 10-K filings.
$75M in FY2024 with a 5-year CAGR of +77.7%.
Improved from $14M to $75M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +146.8%
- 5-Year CAGR
- +77.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 210This company $75.1M Sector average $644.0M
▼
-88.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +77.7%, indicating consistent growth.
- In FY2024, r&d expense increased 7309.7% year-over-year.
- Ranks #162 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $75.1M | +7309.7% |
| FY2023 | $1.0M | -92.7% |
| FY2022 | $13.8M | +177.1% |
| FY2021 | $5.0M | +172.3% |
| FY2020 | $1.8M | -56.8% |
| FY2019 | $4.2M | -69.9% |
| FY2018 | $14.1M | +14.0% |
| FY2017 | $12.3M | +74.8% |
| FY2016 | $7.1M | +25.6% |
| FY2015 | $5.6M | +92.1% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026